Want to see HK:2291 full AI Analyst Report?
2291 Stock Chart & Stats
HK$13.57
HK$0.14(1.03%)
At close: 4:00 PM EDT
HK$13.57
HK$0.14(1.03%)
Day’s Range― - ―
52-Week RangeHK$8.33 - HK$27.60
Previous CloseN/A
Volume1.90M
Average Volume (3M)280.65K
Market Cap
HK$4.13B
Enterprise ValueHK$1.46B
Total Cash (Recent Filing)HK$1.16B
Total Debt (Recent Filing)HK$1.72M
Price to Earnings (P/E)15.1
Beta0.80
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield4.8%
Share Statistics
EPS (TTM)0.68
Shares Outstanding346,750,000
10 Day Avg. Volume228,157
30 Day Avg. Volume280,646
Financial Highlights & Ratios
PEG Ratio-7.43
Price to Book (P/B)2.46
Price to Sales (P/S)9.50
P/FCF Ratio34.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)1.03
Revenue Forecast (FY)HK$751.00M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetExtremely low leverage and minimal debt provide durable financial flexibility: the company can fund operations, R&D, or dividends from internal resources, withstand cyclical shocks, and access capital at lower risk, reducing insolvency and refinancing pressures over months.
High Profitability And MarginsSustained high gross and operating margins signal structural pricing power or cost advantages, enabling strong cash generation and funding for growth or shareholder returns. High margins and recent double-digit ROE support resilient earnings capacity over the medium term.
Improving Cash GenerationA trend of improving operating cash flow and rising free cash flow through 2025 enhances durability: it funds reinvestment, dividends, and buffer for working-capital swings, reducing reliance on external financing and supporting strategic initiatives over the coming months.
Bears Say
2025 Revenue ContractionA year-over-year revenue decline signals weakening demand or competitive pressure that can erode operating leverage and challenge margin sustainability. If recurring, reduced top-line momentum can limit reinvestment capacity and compress profitability over the medium term.
Historical Earnings VolatilityA prior net loss and negative free cash flow in 2022 show earnings and cash sensitivity to adverse conditions. This historical volatility suggests outcomes can swing materially, elevating medium-term execution and demand risk despite recent recovery.
Weak Cash ConversionPersistent FCF-to-net-income below 1 implies earnings quality and working-capital pressures: reported profits do not fully convert to cash, limiting the reliability of cash for capex, debt repayment, or dividends and reducing financial resilience over months.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H News
2291 FAQ
What was LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s price range in the past 12 months?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H lowest stock price was HK$8.33 and its highest was HK$27.60 in the past 12 months.
What is LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s market cap?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s market cap is HK$4.13B.
When is LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s upcoming earnings report date?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s upcoming earnings report date is Aug 20, 2026 which is in 15 days.
How were LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s earnings last quarter?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H released its earnings results on Mar 30, 2026. The company reported HK$0.182 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.182.
Is LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H overvalued?
According to Wall Street analysts LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s price is currently Overvalued.
Does LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H pay dividends?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H pays a Annually dividend of HK$0.573 which represents an annual dividend yield of 4.8%. See more information on LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H dividends here
What is LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s EPS estimate?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H have?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H has 346,750,000 shares outstanding.
What happened to LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H’s price movement after its last earnings report?
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H reported an EPS of HK$0.182 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -0.312%.
Which hedge fund is a major shareholder of LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:2291
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
25.87%
12-Months-Change
Fundamentals
Return on Equity
4.80%
Trailing 12-Months
Asset Growth
5.46%
Trailing 12-Months
Company Description
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd., an investment holding entity, focuses globally on the research, development, production, and marketing of advanced interventional medical devices. The company provides an extensive range of solutions addressing various cardiovascular ailments. This includes specialized treatments for congenital heart defects, such as occluders for atrial septal, ventricular septal, and patent ductus arteriosus, along with necessary delivery systems and snare products. Additionally, it develops technologies for preventing cardioembolic stroke, offering occluders for the left atrial appendage and patent foramen ovale. Its portfolio also features a comprehensive selection of products for managing valvular diseases, including devices for aortic, mitral, tricuspid, and pulmonary valves, complemented by essential procedural accessories. Further offerings encompass vascular plugs and interatrial shunt devices. These medical technologies are primarily distributed to hospitals and through a network of distributors. Founded in 1994, the firm is headquartered in Shanghai, People's Republic of China, and operates as a subsidiary of Lepu Medical Technology (Beijing) Co., Ltd.
LEPU ScienTech Medical Technology (Shanghai) Co., Ltd. Class H (2291) Earnings & Revenues
Technical Analysis
Neusoft Education Technology Co. Limited
―
China Leon Inspection Holding Limited
―
REF Holdings Limited
―
Cornerstone Technologies Holdings Limited
―
EDICO Holdings Limited
―